BGI Genomics Past Earnings Performance
Past criteria checks 0/6
BGI Genomics's earnings have been declining at an average annual rate of -13.8%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 8% per year. BGI Genomics's return on equity is 0.6%, and it has net margins of 1.5%.
Key information
-13.8%
Earnings growth rate
-14.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 8.0% |
| Return on equity | 0.6% |
| Net Margin | 1.5% |
| Next Earnings Update | 24 Aug 2024 |
Recent past performance updates
Recent updates
Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15
Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S
May 22BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings
Apr 21Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Revenue & Expenses Breakdown
How BGI Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,216 | 64 | 1,508 | 508 |
| 31 Dec 23 | 4,350 | 93 | 1,507 | 523 |
| 30 Sep 23 | 5,680 | 126 | 1,832 | 522 |
| 30 Jun 23 | 5,964 | 248 | 1,968 | 527 |
| 31 Mar 23 | 6,578 | 514 | 2,145 | 517 |
| 01 Jan 23 | 7,053 | 803 | 2,183 | 526 |
| 30 Sep 22 | 6,132 | 794 | 1,983 | 513 |
| 30 Jun 22 | 6,281 | 981 | 1,805 | 522 |
| 31 Mar 22 | 6,633 | 1,267 | 1,776 | 513 |
| 01 Jan 22 | 6,766 | 1,462 | 1,742 | 475 |
| 30 Sep 21 | 6,797 | 798 | 2,028 | 709 |
| 30 Jun 21 | 7,936 | 1,523 | 2,019 | 656 |
| 31 Mar 21 | 9,169 | 2,474 | 1,857 | 622 |
| 31 Dec 20 | 8,397 | 2,089 | 1,771 | 611 |
| 30 Sep 20 | 7,480 | 2,712 | 1,160 | 335 |
| 30 Jun 20 | 5,617 | 1,730 | 1,085 | 332 |
| 31 Mar 20 | 3,009 | 318 | 976 | 318 |
| 31 Dec 19 | 2,800 | 276 | 927 | 306 |
| 30 Sep 19 | 2,795 | 337 | 1,004 | 303 |
| 30 Jun 19 | 2,687 | 377 | 878 | 283 |
| 31 Mar 19 | 2,603 | 384 | 836 | 267 |
| 31 Dec 18 | 2,536 | 387 | 792 | 237 |
| 30 Sep 18 | 2,463 | 406 | 696 | 214 |
| 30 Jun 18 | 2,348 | 415 | 602 | 255 |
| 31 Mar 18 | 2,224 | 404 | 602 | 205 |
| 31 Dec 17 | 2,096 | 398 | 611 | 163 |
| 30 Sep 17 | 1,901 | 388 | 630 | 111 |
| 30 Jun 17 | 1,833 | 375 | 747 | 0 |
| 31 Mar 17 | 1,796 | 352 | 852 | 0 |
| 31 Dec 16 | 1,711 | 333 | 725 | 0 |
| 30 Jun 16 | 1,520 | 336 | 555 | 0 |
| 31 Mar 16 | 1,339 | 299 | 357 | 0 |
| 31 Dec 15 | 1,319 | 262 | 460 | 0 |
| 31 Dec 14 | 1,132 | 28 | 452 | 0 |
| 31 Dec 13 | 1,047 | 136 | 358 | 0 |
Quality Earnings: 300676 has a large one-off loss of CN¥31.3M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300676's current net profit margins (1.5%) are lower than last year (7.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300676's earnings have declined by 13.8% per year over the past 5 years.
Accelerating Growth: 300676's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300676 had negative earnings growth (-87.5%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: 300676's Return on Equity (0.6%) is considered low.